| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cough | 107 | 2025 | 182 | 20.100 |
Why?
|
| Periodicals as Topic | 13 | 2020 | 175 | 3.620 |
Why?
|
| Pulmonary Medicine | 8 | 2016 | 41 | 3.330 |
Why?
|
| Chronic Disease | 64 | 2025 | 756 | 2.830 |
Why?
|
| Gastroesophageal Reflux | 24 | 2019 | 89 | 2.460 |
Why?
|
| Asthma | 34 | 2020 | 471 | 2.090 |
Why?
|
| Antitussive Agents | 9 | 2023 | 11 | 2.020 |
Why?
|
| Journal Impact Factor | 5 | 2016 | 26 | 1.700 |
Why?
|
| Humans | 212 | 2025 | 64243 | 1.510 |
Why?
|
| Practice Guidelines as Topic | 24 | 2018 | 726 | 1.370 |
Why?
|
| Publishing | 6 | 2017 | 93 | 1.350 |
Why?
|
| Intensive Care Units | 11 | 2016 | 414 | 1.240 |
Why?
|
| Algorithms | 9 | 2020 | 1028 | 1.180 |
Why?
|
| Critical Illness | 6 | 2020 | 327 | 1.120 |
Why?
|
| Quality of Life | 13 | 2020 | 1257 | 1.100 |
Why?
|
| Hypersensitivity | 3 | 2020 | 65 | 1.090 |
Why?
|
| Evidence-Based Medicine | 15 | 2019 | 462 | 0.970 |
Why?
|
| Thoracic Diseases | 3 | 2017 | 15 | 0.960 |
Why?
|
| Editorial Policies | 4 | 2017 | 55 | 0.940 |
Why?
|
| Adult | 81 | 2025 | 17117 | 0.910 |
Why?
|
| Biomedical Research | 6 | 2015 | 270 | 0.890 |
Why?
|
| Diagnosis, Differential | 25 | 2015 | 984 | 0.830 |
Why?
|
| Nalbuphine | 1 | 2023 | 3 | 0.810 |
Why?
|
| Child | 26 | 2025 | 4583 | 0.790 |
Why?
|
| Bronchi | 6 | 2015 | 84 | 0.790 |
Why?
|
| Tics | 3 | 2015 | 7 | 0.790 |
Why?
|
| Patient-Centered Care | 4 | 2006 | 260 | 0.780 |
Why?
|
| Habits | 3 | 2015 | 21 | 0.780 |
Why?
|
| Critical Care | 6 | 2016 | 403 | 0.770 |
Why?
|
| Disease Management | 6 | 2017 | 237 | 0.770 |
Why?
|
| Bronchitis | 9 | 2020 | 30 | 0.760 |
Why?
|
| Cleft Palate | 1 | 2022 | 40 | 0.750 |
Why?
|
| Scientific Misconduct | 2 | 2013 | 12 | 0.750 |
Why?
|
| Medicine | 2 | 2013 | 56 | 0.720 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 158 | 0.690 |
Why?
|
| Societies, Medical | 4 | 2010 | 381 | 0.680 |
Why?
|
| Tic Disorders | 2 | 2014 | 5 | 0.680 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2020 | 698 | 0.670 |
Why?
|
| Prednisone | 4 | 2015 | 85 | 0.670 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2020 | 7 | 0.640 |
Why?
|
| Ethics, Medical | 2 | 2011 | 40 | 0.630 |
Why?
|
| Common Cold | 5 | 2017 | 9 | 0.630 |
Why?
|
| Bronchoscopy | 7 | 2015 | 90 | 0.600 |
Why?
|
| Respiratory System | 3 | 2015 | 48 | 0.590 |
Why?
|
| Adolescent | 31 | 2025 | 6304 | 0.580 |
Why?
|
| Pneumonia, Ventilator-Associated | 3 | 2015 | 37 | 0.570 |
Why?
|
| Consensus | 7 | 2018 | 185 | 0.570 |
Why?
|
| Reflex | 5 | 2021 | 27 | 0.550 |
Why?
|
| Critical Pathways | 2 | 2016 | 33 | 0.550 |
Why?
|
| Public Health Surveillance | 2 | 2015 | 28 | 0.550 |
Why?
|
| Acute Disease | 14 | 2020 | 672 | 0.550 |
Why?
|
| Respiratory Tract Infections | 7 | 2017 | 90 | 0.550 |
Why?
|
| Complementary Therapies | 2 | 2017 | 63 | 0.540 |
Why?
|
| Patient Care Team | 3 | 2012 | 340 | 0.540 |
Why?
|
| Bronchial Provocation Tests | 11 | 2016 | 17 | 0.520 |
Why?
|
| History, 20th Century | 7 | 2016 | 235 | 0.520 |
Why?
|
| Radiography, Thoracic | 6 | 2015 | 117 | 0.510 |
Why?
|
| Social Behavior | 1 | 2017 | 89 | 0.500 |
Why?
|
| Glucocorticoids | 3 | 2015 | 189 | 0.500 |
Why?
|
| Models, Organizational | 3 | 2012 | 92 | 0.490 |
Why?
|
| Pneumonia | 7 | 2019 | 291 | 0.490 |
Why?
|
| Occupational Exposure | 2 | 2016 | 315 | 0.480 |
Why?
|
| History, 21st Century | 5 | 2016 | 176 | 0.480 |
Why?
|
| Bronchodilator Agents | 7 | 2003 | 119 | 0.480 |
Why?
|
| Polychondritis, Relapsing | 1 | 2015 | 3 | 0.480 |
Why?
|
| Pulmonary Eosinophilia | 2 | 2015 | 11 | 0.480 |
Why?
|
| Thorax | 4 | 2019 | 34 | 0.470 |
Why?
|
| Capnography | 1 | 2015 | 7 | 0.460 |
Why?
|
| Syringes | 1 | 2015 | 12 | 0.460 |
Why?
|
| Teaching | 1 | 2016 | 164 | 0.460 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2015 | 21 | 0.460 |
Why?
|
| Colorimetry | 2 | 2015 | 26 | 0.460 |
Why?
|
| Environment | 1 | 2016 | 123 | 0.450 |
Why?
|
| Carbon Dioxide | 2 | 2015 | 86 | 0.450 |
Why?
|
| Male | 69 | 2025 | 30295 | 0.450 |
Why?
|
| Middle Aged | 56 | 2025 | 17899 | 0.440 |
Why?
|
| Muscle, Smooth | 2 | 2015 | 134 | 0.440 |
Why?
|
| Lung | 12 | 2025 | 964 | 0.430 |
Why?
|
| Prospective Studies | 29 | 2015 | 3315 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 7 | 2018 | 800 | 0.410 |
Why?
|
| Sputum | 6 | 2016 | 43 | 0.400 |
Why?
|
| Severity of Illness Index | 12 | 2025 | 1561 | 0.390 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 478 | 0.390 |
Why?
|
| Catheter Ablation | 1 | 2015 | 155 | 0.390 |
Why?
|
| Australia | 2 | 2023 | 126 | 0.380 |
Why?
|
| Female | 63 | 2025 | 33351 | 0.380 |
Why?
|
| Information Management | 1 | 2012 | 12 | 0.370 |
Why?
|
| Online Systems | 1 | 2012 | 20 | 0.370 |
Why?
|
| Quality of Health Care | 5 | 2016 | 526 | 0.370 |
Why?
|
| Publication Bias | 2 | 2009 | 21 | 0.370 |
Why?
|
| Publications | 1 | 2012 | 29 | 0.370 |
Why?
|
| Plagiarism | 1 | 2012 | 4 | 0.370 |
Why?
|
| Terminology as Topic | 2 | 2013 | 141 | 0.360 |
Why?
|
| United States | 17 | 2020 | 7923 | 0.360 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2011 | 2 | 0.360 |
Why?
|
| Drug Approval | 1 | 2011 | 27 | 0.350 |
Why?
|
| Jurisprudence | 1 | 2011 | 25 | 0.340 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 91 | 0.340 |
Why?
|
| Physicians | 1 | 2016 | 483 | 0.330 |
Why?
|
| Surveys and Questionnaires | 7 | 2025 | 2737 | 0.330 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2018 | 140 | 0.330 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 134 | 0.330 |
Why?
|
| Authorship | 2 | 2012 | 22 | 0.330 |
Why?
|
| Education, Medical | 2 | 2010 | 185 | 0.330 |
Why?
|
| Peer Review, Research | 2 | 2012 | 47 | 0.330 |
Why?
|
| Outpatients | 4 | 2020 | 140 | 0.330 |
Why?
|
| Conflict of Interest | 2 | 2012 | 38 | 0.320 |
Why?
|
| Lung Diseases | 7 | 2004 | 183 | 0.320 |
Why?
|
| Aged | 38 | 2025 | 14648 | 0.310 |
Why?
|
| Lung Diseases, Obstructive | 4 | 2000 | 34 | 0.300 |
Why?
|
| Age Factors | 8 | 2025 | 1569 | 0.300 |
Why?
|
| Public Health | 1 | 2011 | 186 | 0.290 |
Why?
|
| Software | 1 | 2012 | 388 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2019 | 788 | 0.280 |
Why?
|
| Organizational Innovation | 3 | 2017 | 82 | 0.280 |
Why?
|
| Dyspnea | 2 | 2003 | 124 | 0.260 |
Why?
|
| Radiography | 11 | 2005 | 552 | 0.260 |
Why?
|
| Ethics, Research | 1 | 2007 | 20 | 0.260 |
Why?
|
| Clinical Trials as Topic | 3 | 2007 | 460 | 0.260 |
Why?
|
| Health Facility Environment | 1 | 2006 | 3 | 0.260 |
Why?
|
| Smoking | 5 | 2016 | 861 | 0.250 |
Why?
|
| Punctures | 4 | 1991 | 63 | 0.250 |
Why?
|
| Influenza, Human | 3 | 2019 | 212 | 0.250 |
Why?
|
| Rhinitis | 4 | 2016 | 25 | 0.250 |
Why?
|
| Trust | 1 | 2007 | 79 | 0.240 |
Why?
|
| Methacholine Chloride | 8 | 1997 | 23 | 0.240 |
Why?
|
| Research Design | 3 | 2015 | 583 | 0.240 |
Why?
|
| Female Urogenital Diseases | 1 | 2006 | 5 | 0.240 |
Why?
|
| Male Urogenital Diseases | 1 | 2006 | 4 | 0.240 |
Why?
|
| Disclosure | 1 | 2006 | 57 | 0.240 |
Why?
|
| Respiratory Tract Diseases | 2 | 2025 | 38 | 0.240 |
Why?
|
| Workload | 1 | 2006 | 127 | 0.240 |
Why?
|
| Health Priorities | 1 | 2025 | 28 | 0.230 |
Why?
|
| Adolescent Health | 1 | 2025 | 14 | 0.230 |
Why?
|
| Postoperative Complications | 4 | 2002 | 1294 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 71 | 0.230 |
Why?
|
| Safety Management | 1 | 2006 | 137 | 0.230 |
Why?
|
| Child Health | 1 | 2025 | 32 | 0.230 |
Why?
|
| Pneumothorax | 5 | 1992 | 50 | 0.220 |
Why?
|
| Telemedicine | 3 | 2016 | 344 | 0.220 |
Why?
|
| Child, Preschool | 6 | 2020 | 2018 | 0.220 |
Why?
|
| Lung Neoplasms | 6 | 2017 | 695 | 0.220 |
Why?
|
| Environmental Exposure | 2 | 2016 | 220 | 0.220 |
Why?
|
| Mucociliary Clearance | 3 | 2021 | 6 | 0.220 |
Why?
|
| Bacterial Infections | 2 | 2003 | 153 | 0.210 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2003 | 19 | 0.210 |
Why?
|
| Community-Acquired Infections | 1 | 2004 | 94 | 0.210 |
Why?
|
| Pharyngitis | 1 | 2003 | 13 | 0.200 |
Why?
|
| Respiration, Artificial | 3 | 2002 | 296 | 0.200 |
Why?
|
| Neck Pain | 1 | 2003 | 21 | 0.200 |
Why?
|
| Nasal Decongestants | 1 | 2003 | 2 | 0.200 |
Why?
|
| Histamine H1 Antagonists | 1 | 2003 | 10 | 0.200 |
Why?
|
| Suppuration | 1 | 2003 | 11 | 0.200 |
Why?
|
| Prognosis | 6 | 2025 | 1769 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 161 | 0.200 |
Why?
|
| Mediastinal Diseases | 3 | 1997 | 15 | 0.200 |
Why?
|
| Sensitivity and Specificity | 6 | 2015 | 1162 | 0.200 |
Why?
|
| Double-Blind Method | 5 | 2020 | 744 | 0.200 |
Why?
|
| Deglutition Disorders | 1 | 2003 | 40 | 0.200 |
Why?
|
| Osteoarthropathy, Primary Hypertrophic | 1 | 2002 | 1 | 0.200 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 531 | 0.190 |
Why?
|
| Registries | 1 | 2007 | 885 | 0.190 |
Why?
|
| Actinomycosis | 1 | 2002 | 5 | 0.190 |
Why?
|
| Fundoplication | 2 | 2002 | 25 | 0.190 |
Why?
|
| Pyrimidines | 1 | 2023 | 146 | 0.190 |
Why?
|
| Status Asthmaticus | 2 | 2000 | 6 | 0.190 |
Why?
|
| Sulfonamides | 1 | 2023 | 131 | 0.190 |
Why?
|
| Whooping Cough | 2 | 2018 | 10 | 0.190 |
Why?
|
| Ventilator Weaning | 1 | 2002 | 20 | 0.190 |
Why?
|
| Patient Admission | 2 | 2003 | 198 | 0.180 |
Why?
|
| Pharmaceutical Solutions | 1 | 2002 | 3 | 0.180 |
Why?
|
| Nose Diseases | 1 | 2002 | 9 | 0.180 |
Why?
|
| Paranasal Sinuses | 1 | 2002 | 8 | 0.180 |
Why?
|
| Capsaicin | 1 | 2002 | 20 | 0.180 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2001 | 9 | 0.170 |
Why?
|
| Methacholine Compounds | 11 | 1991 | 12 | 0.170 |
Why?
|
| Mouthwashes | 1 | 2020 | 5 | 0.170 |
Why?
|
| Lung Diseases, Fungal | 1 | 2001 | 35 | 0.170 |
Why?
|
| Antisepsis | 1 | 2020 | 7 | 0.170 |
Why?
|
| Thrombophlebitis | 3 | 1997 | 14 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2020 | 2604 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 22 | 0.170 |
Why?
|
| Aspergillosis | 1 | 2001 | 41 | 0.170 |
Why?
|
| Length of Stay | 5 | 2016 | 818 | 0.170 |
Why?
|
| Aspergillus fumigatus | 1 | 2001 | 54 | 0.170 |
Why?
|
| Pneumonectomy | 2 | 1998 | 116 | 0.170 |
Why?
|
| Vagus Nerve | 1 | 2020 | 21 | 0.160 |
Why?
|
| Delphi Technique | 5 | 2019 | 102 | 0.160 |
Why?
|
| Otolaryngology | 2 | 2011 | 28 | 0.160 |
Why?
|
| Receptors, Purinergic P2X3 | 1 | 2020 | 5 | 0.160 |
Why?
|
| Bronchitis, Chronic | 1 | 2020 | 17 | 0.160 |
Why?
|
| Risk Factors | 6 | 2025 | 5339 | 0.160 |
Why?
|
| Expectorants | 4 | 1998 | 4 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2020 | 37 | 0.150 |
Why?
|
| Pneumonia, Aspiration | 3 | 1992 | 17 | 0.150 |
Why?
|
| Asthma, Exercise-Induced | 2 | 2016 | 3 | 0.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2010 | 143 | 0.150 |
Why?
|
| Triiodothyronine | 2 | 1991 | 30 | 0.140 |
Why?
|
| Heart Injuries | 1 | 1998 | 20 | 0.140 |
Why?
|
| Chest Tubes | 1 | 1998 | 17 | 0.140 |
Why?
|
| Esophagus | 5 | 2000 | 49 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 214 | 0.140 |
Why?
|
| Bronchiolitis, Viral | 1 | 2018 | 4 | 0.140 |
Why?
|
| Trachea | 5 | 1982 | 85 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 848 | 0.140 |
Why?
|
| Femoral Vein | 1 | 1997 | 18 | 0.140 |
Why?
|
| Metaproterenol | 1 | 1997 | 2 | 0.140 |
Why?
|
| Bronchoconstrictor Agents | 1 | 1997 | 5 | 0.140 |
Why?
|
| Administration, Inhalation | 3 | 2006 | 158 | 0.140 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 34 | 0.130 |
Why?
|
| Nonprescription Drugs | 1 | 2017 | 17 | 0.130 |
Why?
|
| Hospital Mortality | 4 | 2014 | 870 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 107 | 0.130 |
Why?
|
| Respiratory Function Tests | 10 | 2002 | 190 | 0.130 |
Why?
|
| Echo-Planar Imaging | 1 | 1997 | 34 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2017 | 73 | 0.130 |
Why?
|
| Multimedia | 1 | 2017 | 9 | 0.130 |
Why?
|
| Vocal Cord Dysfunction | 1 | 2016 | 1 | 0.130 |
Why?
|
| Spinal Nerve Roots | 1 | 2017 | 18 | 0.130 |
Why?
|
| Catheterization, Central Venous | 1 | 1997 | 83 | 0.130 |
Why?
|
| Procainamide | 1 | 1996 | 6 | 0.130 |
Why?
|
| Oxygen | 3 | 1995 | 321 | 0.130 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1996 | 5 | 0.130 |
Why?
|
| Electric Stimulation Therapy | 1 | 2017 | 27 | 0.130 |
Why?
|
| Biopsy | 4 | 2015 | 447 | 0.130 |
Why?
|
| Asthma, Occupational | 1 | 2016 | 2 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 1998 | 265 | 0.130 |
Why?
|
| Fecal Incontinence | 1 | 2017 | 32 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 108 | 0.120 |
Why?
|
| Sarcoma, Kaposi | 1 | 1996 | 17 | 0.120 |
Why?
|
| Probability | 3 | 2005 | 169 | 0.120 |
Why?
|
| Musculoskeletal Diseases | 1 | 1997 | 103 | 0.120 |
Why?
|
| Sex Factors | 3 | 2021 | 979 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2025 | 2046 | 0.120 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 116 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2017 | 498 | 0.120 |
Why?
|
| Image Enhancement | 1 | 1997 | 193 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2016 | 126 | 0.120 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 103 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 205 | 0.120 |
Why?
|
| Sickness Impact Profile | 3 | 2005 | 46 | 0.120 |
Why?
|
| Decision Support Techniques | 2 | 2011 | 192 | 0.120 |
Why?
|
| Sinusitis | 3 | 2000 | 31 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2018 | 329 | 0.120 |
Why?
|
| Somatoform Disorders | 1 | 2015 | 15 | 0.120 |
Why?
|
| Exhalation | 1 | 2015 | 15 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 254 | 0.110 |
Why?
|
| Helium | 1 | 1995 | 7 | 0.110 |
Why?
|
| Aging | 1 | 2021 | 754 | 0.110 |
Why?
|
| Brachiocephalic Trunk | 1 | 1995 | 16 | 0.110 |
Why?
|
| Incidence | 3 | 2005 | 1383 | 0.110 |
Why?
|
| Clinical Protocols | 4 | 2001 | 135 | 0.110 |
Why?
|
| Fistula | 1 | 1995 | 15 | 0.110 |
Why?
|
| Athletes | 1 | 2016 | 109 | 0.110 |
Why?
|
| Treatment Outcome | 8 | 2017 | 5691 | 0.110 |
Why?
|
| Tracheal Diseases | 1 | 1995 | 12 | 0.110 |
Why?
|
| Contrast Media | 1 | 1997 | 429 | 0.110 |
Why?
|
| Airway Obstruction | 3 | 1984 | 38 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 54 | 0.110 |
Why?
|
| Electrocardiography | 2 | 1996 | 554 | 0.110 |
Why?
|
| Young Adult | 6 | 2025 | 4776 | 0.110 |
Why?
|
| Suction | 4 | 1983 | 35 | 0.110 |
Why?
|
| Models, Animal | 1 | 2015 | 240 | 0.110 |
Why?
|
| Pleural Effusion | 3 | 1997 | 40 | 0.110 |
Why?
|
| APACHE | 3 | 2016 | 43 | 0.110 |
Why?
|
| Swine | 1 | 2015 | 394 | 0.110 |
Why?
|
| Anxiety | 1 | 2017 | 430 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 318 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1272 | 0.100 |
Why?
|
| Time Factors | 4 | 2010 | 3724 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2005 | 2478 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2017 | 479 | 0.100 |
Why?
|
| Physician-Patient Relations | 2 | 2006 | 424 | 0.100 |
Why?
|
| Biomedical Technology | 1 | 2012 | 6 | 0.090 |
Why?
|
| Age Distribution | 2 | 2004 | 258 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 5 | 1999 | 462 | 0.090 |
Why?
|
| Policy Making | 1 | 2012 | 48 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2010 | 607 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 1669 | 0.090 |
Why?
|
| Mass Screening | 1 | 2017 | 693 | 0.090 |
Why?
|
| Thyrotoxicosis | 1 | 1991 | 7 | 0.090 |
Why?
|
| Obesity | 1 | 1999 | 1247 | 0.090 |
Why?
|
| Ethics, Professional | 1 | 2011 | 5 | 0.090 |
Why?
|
| Patient Rights | 1 | 2011 | 15 | 0.090 |
Why?
|
| Oropharynx | 2 | 1982 | 12 | 0.090 |
Why?
|
| Lung Abscess | 2 | 1981 | 6 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2011 | 306 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 1992 | 154 | 0.080 |
Why?
|
| Nasal Mucosa | 3 | 1996 | 18 | 0.080 |
Why?
|
| Academic Medical Centers | 4 | 2016 | 313 | 0.080 |
Why?
|
| Depression | 1 | 2017 | 909 | 0.080 |
Why?
|
| Amitriptyline | 1 | 2010 | 7 | 0.080 |
Why?
|
| Vagotomy | 1 | 2010 | 6 | 0.080 |
Why?
|
| Hemothorax | 1 | 1990 | 8 | 0.080 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2010 | 13 | 0.080 |
Why?
|
| Speech Therapy | 1 | 2010 | 16 | 0.080 |
Why?
|
| Thoracic Vertebrae | 1 | 1990 | 35 | 0.080 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1990 | 24 | 0.080 |
Why?
|
| Respiratory Hypersensitivity | 1 | 1989 | 12 | 0.080 |
Why?
|
| Monitoring, Physiologic | 3 | 1999 | 163 | 0.080 |
Why?
|
| Forced Expiratory Volume | 6 | 2003 | 209 | 0.080 |
Why?
|
| Sterilization | 1 | 1989 | 15 | 0.080 |
Why?
|
| Public Opinion | 1 | 2009 | 25 | 0.080 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1989 | 43 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 107 | 0.070 |
Why?
|
| Disinfection | 1 | 1989 | 22 | 0.070 |
Why?
|
| Aged, 80 and over | 9 | 2015 | 5520 | 0.070 |
Why?
|
| Truth Disclosure | 1 | 2009 | 58 | 0.070 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2000 | 60 | 0.070 |
Why?
|
| Global Health | 1 | 2010 | 183 | 0.070 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1988 | 4 | 0.070 |
Why?
|
| Radionuclide Imaging | 4 | 1997 | 128 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 1990 | 143 | 0.070 |
Why?
|
| Spirometry | 5 | 1989 | 112 | 0.070 |
Why?
|
| Gastric Mucosa | 1 | 1988 | 52 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 1992 | 383 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2004 | 209 | 0.070 |
Why?
|
| Diagnosis-Related Groups | 2 | 2011 | 87 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2000 | 1102 | 0.070 |
Why?
|
| Histamine | 4 | 1990 | 21 | 0.070 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2007 | 4 | 0.070 |
Why?
|
| Pulmonary Alveoli | 2 | 1985 | 43 | 0.060 |
Why?
|
| Health Status Indicators | 2 | 2010 | 95 | 0.060 |
Why?
|
| Staining and Labeling | 2 | 1985 | 126 | 0.060 |
Why?
|
| Quality Control | 1 | 2007 | 74 | 0.060 |
Why?
|
| Reference Values | 2 | 2004 | 331 | 0.060 |
Why?
|
| Knee | 2 | 2002 | 40 | 0.060 |
Why?
|
| Physician-Nurse Relations | 1 | 2006 | 26 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 1681 | 0.060 |
Why?
|
| Writing | 1 | 2007 | 44 | 0.060 |
Why?
|
| Metered Dose Inhalers | 1 | 2006 | 16 | 0.060 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2006 | 19 | 0.060 |
Why?
|
| Communication Barriers | 1 | 2006 | 68 | 0.060 |
Why?
|
| Gentian Violet | 1 | 1985 | 3 | 0.060 |
Why?
|
| Phenazines | 1 | 1985 | 10 | 0.060 |
Why?
|
| Heart Rate | 2 | 1991 | 327 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 137 | 0.060 |
Why?
|
| Hyperthyroidism | 1 | 1985 | 19 | 0.060 |
Why?
|
| Biomechanical Phenomena | 2 | 2021 | 273 | 0.060 |
Why?
|
| Thoracic Surgery | 1 | 1986 | 76 | 0.060 |
Why?
|
| Iatrogenic Disease | 2 | 2011 | 58 | 0.060 |
Why?
|
| Access to Information | 1 | 2005 | 30 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2005 | 42 | 0.060 |
Why?
|
| Mucus | 3 | 1990 | 15 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 214 | 0.060 |
Why?
|
| Laryngoscopy | 2 | 2001 | 61 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2025 | 99 | 0.050 |
Why?
|
| Medical Errors | 1 | 2006 | 198 | 0.050 |
Why?
|
| Colony Count, Microbial | 1 | 2004 | 59 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 119 | 0.050 |
Why?
|
| Bacteriological Techniques | 2 | 1981 | 30 | 0.050 |
Why?
|
| Retrospective Studies | 7 | 2003 | 6726 | 0.050 |
Why?
|
| Nursing | 1 | 2004 | 15 | 0.050 |
Why?
|
| Public Policy | 1 | 2004 | 41 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 158 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 1985 | 223 | 0.050 |
Why?
|
| Albuterol | 1 | 2003 | 24 | 0.050 |
Why?
|
| Drug Stability | 3 | 2002 | 144 | 0.050 |
Why?
|
| Focus Groups | 1 | 2025 | 310 | 0.050 |
Why?
|
| Emergency Treatment | 1 | 2003 | 58 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2002 | 293 | 0.050 |
Why?
|
| Drug Storage | 2 | 2002 | 22 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 438 | 0.050 |
Why?
|
| Bacteria | 3 | 1985 | 317 | 0.050 |
Why?
|
| Health Status | 1 | 2025 | 447 | 0.050 |
Why?
|
| Fingers | 1 | 2002 | 48 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2003 | 164 | 0.050 |
Why?
|
| Cost Control | 1 | 2002 | 24 | 0.050 |
Why?
|
| Gastric Acidity Determination | 1 | 2002 | 5 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2010 | 794 | 0.050 |
Why?
|
| Thyroiditis | 1 | 1982 | 11 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2002 | 230 | 0.050 |
Why?
|
| Mycobacterium Infections | 1 | 1982 | 16 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2003 | 374 | 0.050 |
Why?
|
| Antigens, Helminth | 1 | 2002 | 9 | 0.050 |
Why?
|
| Mycobacterium | 1 | 1982 | 37 | 0.050 |
Why?
|
| Cross Infection | 2 | 1982 | 167 | 0.050 |
Why?
|
| Arrhythmia, Sinus | 1 | 1981 | 3 | 0.050 |
Why?
|
| Respiratory Sounds | 3 | 1989 | 22 | 0.040 |
Why?
|
| Occupational Diseases | 2 | 2016 | 267 | 0.040 |
Why?
|
| Communication | 1 | 2006 | 587 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2002 | 251 | 0.040 |
Why?
|
| Drug Overdose | 1 | 2003 | 122 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 1982 | 80 | 0.040 |
Why?
|
| Bronchiectasis | 2 | 1998 | 13 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 620 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2002 | 79 | 0.040 |
Why?
|
| Infant | 2 | 2017 | 1664 | 0.040 |
Why?
|
| Iodine Radioisotopes | 2 | 1997 | 58 | 0.040 |
Why?
|
| Macrophages | 2 | 1985 | 1053 | 0.040 |
Why?
|
| Neuromuscular Diseases | 1 | 2021 | 22 | 0.040 |
Why?
|
| Light | 1 | 2002 | 204 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 487 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2004 | 1130 | 0.040 |
Why?
|
| Specimen Handling | 1 | 1981 | 61 | 0.040 |
Why?
|
| Empyema | 1 | 1980 | 5 | 0.040 |
Why?
|
| Temperature | 1 | 2002 | 312 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2020 | 29 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 42 | 0.040 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 1980 | 28 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 650 | 0.040 |
Why?
|
| Laryngostenosis | 1 | 2000 | 1 | 0.040 |
Why?
|
| Pneumococcal Infections | 1 | 1980 | 38 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 1998 | 374 | 0.040 |
Why?
|
| Weight Loss | 1 | 2002 | 273 | 0.040 |
Why?
|
| Animals | 4 | 2015 | 20962 | 0.040 |
Why?
|
| Acinetobacter Infections | 1 | 1980 | 6 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 16 | 0.040 |
Why?
|
| Risk | 3 | 1991 | 379 | 0.040 |
Why?
|
| Methylene Blue | 1 | 1980 | 22 | 0.040 |
Why?
|
| Proton-Translocating ATPases | 1 | 1999 | 6 | 0.040 |
Why?
|
| Medical History Taking | 3 | 1996 | 68 | 0.040 |
Why?
|
| Omeprazole | 1 | 1999 | 5 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2020 | 49 | 0.040 |
Why?
|
| Ventilators, Mechanical | 1 | 1980 | 30 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2003 | 507 | 0.040 |
Why?
|
| Research | 1 | 2001 | 196 | 0.040 |
Why?
|
| Antacids | 1 | 1999 | 14 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2000 | 200 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2000 | 41 | 0.040 |
Why?
|
| Syndrome | 2 | 2015 | 180 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 2616 | 0.040 |
Why?
|
| Bronchial Spasm | 2 | 1989 | 8 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 44 | 0.040 |
Why?
|
| Rupture | 1 | 1998 | 24 | 0.040 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2018 | 14 | 0.040 |
Why?
|
| Goiter | 1 | 1978 | 9 | 0.040 |
Why?
|
| Basement Membrane | 2 | 1975 | 25 | 0.040 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 21 | 0.040 |
Why?
|
| Comorbidity | 1 | 2001 | 1118 | 0.040 |
Why?
|
| Steroids | 1 | 1998 | 55 | 0.040 |
Why?
|
| Nurses | 1 | 1999 | 109 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 1978 | 33 | 0.030 |
Why?
|
| Goiter, Substernal | 1 | 1997 | 2 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 1978 | 82 | 0.030 |
Why?
|
| Mediastinal Emphysema | 2 | 1992 | 6 | 0.030 |
Why?
|
| Peptostreptococcus | 1 | 1997 | 1 | 0.030 |
Why?
|
| Empyema, Pleural | 1 | 1997 | 3 | 0.030 |
Why?
|
| Bacteroides Infections | 1 | 1997 | 5 | 0.030 |
Why?
|
| Aneurysm | 2 | 1988 | 58 | 0.030 |
Why?
|
| Embolism, Air | 2 | 1992 | 10 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 373 | 0.030 |
Why?
|
| Pulmonary Artery | 2 | 1988 | 97 | 0.030 |
Why?
|
| Infectious Mononucleosis | 1 | 1997 | 34 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2002 | 551 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 30 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 1997 | 163 | 0.030 |
Why?
|
| Nutritional Support | 1 | 1997 | 12 | 0.030 |
Why?
|
| Exercise | 2 | 2016 | 954 | 0.030 |
Why?
|
| Hospital Bed Capacity, 500 and over | 2 | 2011 | 8 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2017 | 38 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 181 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 172 | 0.030 |
Why?
|
| Sacrum | 1 | 2017 | 27 | 0.030 |
Why?
|
| Skin Tests | 1 | 2016 | 18 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 1977 | 55 | 0.030 |
Why?
|
| Physical Examination | 2 | 1990 | 111 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2016 | 37 | 0.030 |
Why?
|
| Marijuana Smoking | 1 | 2016 | 19 | 0.030 |
Why?
|
| Hemorrhage | 2 | 1995 | 274 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 37 | 0.030 |
Why?
|
| Nursing Homes | 1 | 1982 | 672 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1996 | 93 | 0.030 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 1975 | 8 | 0.030 |
Why?
|
| Corynebacterium | 1 | 1975 | 2 | 0.030 |
Why?
|
| Visual Analog Scale | 1 | 2015 | 9 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1996 | 75 | 0.030 |
Why?
|
| Fever | 1 | 1975 | 66 | 0.030 |
Why?
|
| Meningococcal Infections | 1 | 1975 | 21 | 0.030 |
Why?
|
| Hydrochlorothiazide | 1 | 1994 | 3 | 0.030 |
Why?
|
| Lisinopril | 1 | 1994 | 4 | 0.030 |
Why?
|
| Tetrazoles | 1 | 1994 | 22 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 1994 | 22 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1997 | 296 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 1994 | 33 | 0.030 |
Why?
|
| Antibodies | 1 | 1975 | 186 | 0.030 |
Why?
|
| Tracheostomy | 1 | 1995 | 37 | 0.030 |
Why?
|
| Sleep Stages | 1 | 1994 | 17 | 0.030 |
Why?
|
| Confusion | 1 | 1994 | 17 | 0.030 |
Why?
|
| Imidazoles | 1 | 1994 | 84 | 0.030 |
Why?
|
| Psychometrics | 2 | 2010 | 385 | 0.030 |
Why?
|
| Cell Wall | 1 | 1975 | 120 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1994 | 65 | 0.030 |
Why?
|
| Hemosiderosis | 1 | 1974 | 2 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 1995 | 82 | 0.030 |
Why?
|
| Hospitalization | 2 | 1998 | 1368 | 0.030 |
Why?
|
| Gastric Acid | 1 | 1993 | 10 | 0.030 |
Why?
|
| Bronchial Diseases | 1 | 1973 | 13 | 0.030 |
Why?
|
| Pulmonary Fibrosis | 2 | 1991 | 79 | 0.030 |
Why?
|
| Efferent Pathways | 1 | 1993 | 13 | 0.030 |
Why?
|
| Afferent Pathways | 1 | 1993 | 18 | 0.030 |
Why?
|
| Genetic Variation | 1 | 1975 | 387 | 0.020 |
Why?
|
| Fetus | 1 | 1992 | 100 | 0.020 |
Why?
|
| Fiber Optic Technology | 2 | 1983 | 24 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1992 | 153 | 0.020 |
Why?
|
| Patient Safety | 1 | 2014 | 243 | 0.020 |
Why?
|
| Thyroid Function Tests | 1 | 1991 | 14 | 0.020 |
Why?
|
| Zirconium | 1 | 1991 | 5 | 0.020 |
Why?
|
| Half-Life | 1 | 1991 | 79 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 335 | 0.020 |
Why?
|
| Pressure Ulcer | 1 | 2011 | 34 | 0.020 |
Why?
|
| Catheterization | 2 | 1990 | 113 | 0.020 |
Why?
|
| HIV Infections | 1 | 2017 | 976 | 0.020 |
Why?
|
| Vital Capacity | 2 | 1982 | 118 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1407 | 0.020 |
Why?
|
| Paraplegia | 1 | 1990 | 7 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 113 | 0.020 |
Why?
|
| Hypertension | 1 | 1994 | 593 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 759 | 0.020 |
Why?
|
| Equipment Failure | 1 | 1989 | 68 | 0.020 |
Why?
|
| Gastrointestinal Contents | 1 | 1988 | 6 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1988 | 156 | 0.020 |
Why?
|
| Ultrasonography | 2 | 1990 | 486 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 1996 | 854 | 0.020 |
Why?
|
| Exercise Test | 1 | 1989 | 254 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1988 | 296 | 0.020 |
Why?
|
| Rabbits | 1 | 1988 | 333 | 0.020 |
Why?
|
| Differential Threshold | 1 | 1987 | 1 | 0.020 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1987 | 2 | 0.020 |
Why?
|
| Plethysmography, Impedance | 1 | 1987 | 3 | 0.020 |
Why?
|
| Respiratory Muscles | 1 | 1987 | 16 | 0.020 |
Why?
|
| Reaction Time | 1 | 1987 | 126 | 0.020 |
Why?
|
| Intubation, Intratracheal | 2 | 1981 | 203 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 1987 | 202 | 0.010 |
Why?
|
| Airway Resistance | 1 | 1985 | 8 | 0.010 |
Why?
|
| Social Responsibility | 1 | 2005 | 12 | 0.010 |
Why?
|
| Pregnancy | 1 | 1992 | 2370 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 1987 | 176 | 0.010 |
Why?
|
| Epithelial Cells | 2 | 1980 | 401 | 0.010 |
Why?
|
| Research Personnel | 1 | 2005 | 94 | 0.010 |
Why?
|
| Thyroid (USP) | 1 | 1982 | 1 | 0.010 |
Why?
|
| Streptococcus | 1 | 1982 | 18 | 0.010 |
Why?
|
| Indomethacin | 1 | 1982 | 22 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1984 | 869 | 0.010 |
Why?
|
| Thyroxine | 1 | 1982 | 55 | 0.010 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 1981 | 2 | 0.010 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 1981 | 5 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1981 | 41 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1981 | 79 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1980 | 66 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1980 | 34 | 0.010 |
Why?
|
| Rhinitis, Vasomotor | 1 | 1980 | 1 | 0.010 |
Why?
|
| Hygiene | 1 | 1980 | 13 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 1979 | 6 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 1979 | 12 | 0.010 |
Why?
|
| Laryngeal Cartilages | 1 | 1979 | 3 | 0.010 |
Why?
|
| Hemoptysis | 1 | 1979 | 8 | 0.010 |
Why?
|
| Platelet Count | 1 | 1979 | 26 | 0.010 |
Why?
|
| Subcutaneous Emphysema | 1 | 1979 | 3 | 0.010 |
Why?
|
| Rhode Island | 1 | 1980 | 104 | 0.010 |
Why?
|
| Hand | 1 | 1980 | 73 | 0.010 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1979 | 2 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1980 | 138 | 0.010 |
Why?
|
| Kveim Test | 1 | 1978 | 1 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1978 | 19 | 0.010 |
Why?
|
| Granuloma | 1 | 1978 | 43 | 0.010 |
Why?
|
| Mediastinum | 1 | 1978 | 29 | 0.010 |
Why?
|
| Guaifenesin | 1 | 1977 | 1 | 0.010 |
Why?
|
| Retropharyngeal Abscess | 1 | 1997 | 2 | 0.010 |
Why?
|
| Bacteria, Anaerobic | 1 | 1997 | 5 | 0.010 |
Why?
|
| Mediastinitis | 1 | 1997 | 4 | 0.010 |
Why?
|
| Mouth, Edentulous | 1 | 1977 | 3 | 0.010 |
Why?
|
| Massachusetts | 1 | 2003 | 2094 | 0.010 |
Why?
|
| Linear Models | 1 | 1998 | 407 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1998 | 153 | 0.010 |
Why?
|
| Nutrition Disorders | 1 | 1997 | 7 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2002 | 483 | 0.010 |
Why?
|
| Food, Formulated | 1 | 1997 | 10 | 0.010 |
Why?
|
| Death, Sudden | 1 | 1977 | 30 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 1977 | 65 | 0.010 |
Why?
|
| Health Surveys | 1 | 1998 | 314 | 0.010 |
Why?
|
| Respiration | 1 | 1977 | 92 | 0.010 |
Why?
|
| Food | 1 | 1977 | 76 | 0.010 |
Why?
|
| Erythrocytes | 2 | 1974 | 150 | 0.010 |
Why?
|
| Penicillin G Procaine | 1 | 1975 | 1 | 0.010 |
Why?
|
| Adenoviridae Infections | 1 | 1975 | 5 | 0.010 |
Why?
|
| Remission Induction | 1 | 1995 | 147 | 0.010 |
Why?
|
| Penicillin Resistance | 1 | 1975 | 11 | 0.010 |
Why?
|
| Tetracycline | 1 | 1975 | 24 | 0.010 |
Why?
|
| Calcium | 1 | 1978 | 580 | 0.010 |
Why?
|
| Losartan | 1 | 1994 | 19 | 0.010 |
Why?
|
| Diphosphoglyceric Acids | 1 | 1974 | 2 | 0.010 |
Why?
|
| Cheyne-Stokes Respiration | 1 | 1994 | 3 | 0.010 |
Why?
|
| Oxyhemoglobins | 1 | 1974 | 9 | 0.010 |
Why?
|
| Sinus of Valsalva | 1 | 1994 | 7 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 412 | 0.010 |
Why?
|
| Neisseria meningitidis | 1 | 1975 | 78 | 0.010 |
Why?
|
| Hemosiderin | 1 | 1974 | 1 | 0.010 |
Why?
|
| Fibrin | 1 | 1974 | 19 | 0.010 |
Why?
|
| Glycogen | 1 | 1974 | 42 | 0.010 |
Why?
|
| Pulmonary Edema | 1 | 1974 | 30 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1974 | 212 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 1973 | 25 | 0.010 |
Why?
|
| Aortic Aneurysm | 1 | 1994 | 82 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1974 | 136 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1974 | 234 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1974 | 251 | 0.010 |
Why?
|
| Leukocytes | 1 | 1974 | 103 | 0.010 |
Why?
|
| Collagen | 1 | 1974 | 124 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 2 | 1987 | 7 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1974 | 180 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1974 | 279 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1991 | 110 | 0.010 |
Why?
|
| Echocardiography | 1 | 1994 | 509 | 0.010 |
Why?
|
| Hematoma | 1 | 1990 | 80 | 0.000 |
Why?
|
| Needles | 1 | 1990 | 70 | 0.000 |
Why?
|
| Bronchiolitis Obliterans | 1 | 1989 | 23 | 0.000 |
Why?
|
| History, 18th Century | 1 | 1988 | 9 | 0.000 |
Why?
|
| History, 19th Century | 1 | 1988 | 42 | 0.000 |
Why?
|
| Brompheniramine | 1 | 1988 | 1 | 0.000 |
Why?
|
| Ephedrine | 1 | 1988 | 2 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 201 | 0.000 |
Why?
|
| Pain | 1 | 1990 | 407 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1988 | 467 | 0.000 |
Why?
|
| Phlebography | 1 | 1987 | 44 | 0.000 |
Why?
|
| Drug Contamination | 1 | 1985 | 13 | 0.000 |
Why?
|
| Solutions | 1 | 1985 | 64 | 0.000 |
Why?
|
| Embolization, Therapeutic | 1 | 1988 | 326 | 0.000 |
Why?
|
| Tuberculosis, Miliary | 1 | 1979 | 3 | 0.000 |
Why?
|
| Acid-Base Equilibrium | 1 | 1974 | 7 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1974 | 28 | 0.000 |
Why?
|
| Angina Pectoris | 1 | 1974 | 38 | 0.000 |
Why?
|
| Altitude | 1 | 1974 | 15 | 0.000 |
Why?
|
| Acidosis | 1 | 1974 | 27 | 0.000 |
Why?
|
| Hormones | 1 | 1974 | 60 | 0.000 |
Why?
|
| Phosphates | 1 | 1974 | 93 | 0.000 |
Why?
|
| Hypoxia | 1 | 1974 | 116 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1974 | 104 | 0.000 |
Why?
|
| Dogs | 1 | 1974 | 332 | 0.000 |
Why?
|
| Anemia | 1 | 1974 | 128 | 0.000 |
Why?
|
| Liver Diseases | 1 | 1974 | 160 | 0.000 |
Why?
|
| Blood Glucose | 1 | 1974 | 486 | 0.000 |
Why?
|
| Alcoholism | 1 | 1974 | 323 | 0.000 |
Why?
|
| Rats | 1 | 1974 | 2005 | 0.000 |
Why?
|